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INTRODUCTION
Breast cancer is known to be one of the most common
female cancers in industrialized countries around the world.
Also, the number of women suffering from breast cancer in
developing countries has recently been increasing (1). Breast
cancer is also the most common cause of death in cancer
patients (2). In Korea, it ranks as the 3rd most common
female cancer (3-5) and its mortality rate is 4.2 per 100,000
women, which accounted for more than 970 deaths in 1998
(6).
It has been reported that the factors that affect the prog-
nosis of breast cancer after diagnosis include race (7, 8), age
(7, 9-12), menopause (9, 13-15), period of disease (16), metas-
tasis to the axillary lymph nodes (11, 17), estrogen receptors
(18, 19), and weight, etc. Body size may also be related to
prognosis in women with breast cancer. This relationship
was first reported by Abe et al. (20), who studied obesity in
Japanese women with breast cancer. After this several other
investigators have studied the effect of body size on progno-
sis in breast cancer. Many investigators have found adverse
effects associated with increased body size, whereas others
have reported no effects (21). Commonly, in such studies
body weight and body mass index (BMI) have been chosen
as variables that represent body size.
The purpose of this study was to integrate the relationship
between BMI, which is an indicator of body size, and prog-
nosis in breast cancer by meta-analysis.
MATERIALS AND METHODS
Data collection 
The materials used in this study were articles concerning
the relationship between BMI and prognosis in breast can-
cer that were published in English between January 1966
and December 1999. Information was retrieved from the
MEDLINE (only English publications) databases. In addition,
the cited references in published articles were also reviewed
for relevant results. The medical subject headings for this
search were breast cancer, prognosis, survival, body size, BMI,
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Is Body Mass Index the Prognostic Factor in Breast Cancer?
: A Meta-Analysis
This study was performed to integrate the results of previous studies that inves-
tigated the relationship between body mass index (BMI) and prognosis in breast
cancer. We reviewed the English literatures using the MEDLINE database from
1966 to 1999. The materials included 12 published articles with a total of 8,029
cases of breast cancer. The effect size was obtained from hazard ratio in each
study. Homogeneity test was conducted before the integration of each effect size
and the result demonstrated that the studies were heterogeneous. A random
effect model was used to integrate the overall effect size. The integrated effect
size was 1.56 (95% confidence interval, 1.22-2.00). In addition, publication bias
should be accounted for because each published study was asymmetric in shape
revealed by funnel plot. These results suggest that BMI have a prognostic signif-
icance in breast cancer. We believe that well-designed longitudinal studies, involv-
ing a large number of samples are required to resolve these issues.
Key Words : Breast Neoplasms; Prognosis; Body Mass Index; Meta-Analysis
and Quetelet’s index. 
Meta-analysis 
A total of 22 articles, which contained the above informa-
tion, were selected and evaluated thoroughly by two review-
ers. The agreement rate to the quality evaluation of each
article between the two reviewers was 87.4%, and disagree-
ments were adjusted by mutual consensus. The criteria for
excluding articles for quantitative meta-analysis were as fol-
lows: i) articles that only compared survival rates versus BMI
categories or ii) articles that researched the association bet-
ween patient death without follow-up and BMI. In particu-
lar, the following standards were used for assessing the in-
clusion criteria of articles before applying the meta-analysis,
and those that did not meet the standards were excluded
from the analysis, even though they provided information
for integrating effect size. Firstly, only original articles were
used for the evaluation. Secondly, the investigators should
have confirmed patient deaths with follow-up. Thirdly, the
hazard ratio (effect size) and the 95% confidence interval
(CI) must be included as the information about the relation-
ship between BMI and prognosis in breast cancer, and be
determined using Cox’s proportional hazard model. Adopt-
ing these criteria allowed twelve studies to be included in
the meta-analysis.  
The following information was collected from each study:
the name of the first author, the year of publication, the coun-
try, the number of subjects, menopause state, definition of
BMI including cut-off, effect size, 95% CI, etc. Particularly,
the category of BMI in 12 studies was usually partitioned
into binary, tertile, quartile, or quintiles. Therefore, we select-
ed articles that were divisible into binary categories, to com-
pare only the highest and lowest level of BMI. This method
addresses only the question of the risk ratio between the ex-
treme categories of exposure.
If the hazard ratio of breast cancer prognosis associated
with the BMI was expressed in more than one way, the esti-
mate extracted from the study was the one that reflected the
greatest degree of controlling for confounders. Because few
studies provided complete data for pre- and post-menopausal
women separate, we chose the hazard ratio for the whole
group if available.
The relationship between BMI and prognosis in breast
cancer was assessed by the estimation of the effect size and
95% CI. In three studies (22-24), only the hazard ratio and
the p-value were described, so we computed 95% CI of the
hazard ratio by Greenland’s method (25). 
To estimate the overall effect size, fixed-effects model and
random-effects model were used. A general variance-based
method using the confidence intervals based on the assump-
tion of fixed effects was used for calculating the overall effect
size, 95% CI, and Q statistics by Greenland (25), Prentice
and Thomas (26). Because heterogeneity was assessed by the
homogeneity test, we presented the overall effect size using
the random-effects model as developed by DerSimonian and
Laird (27). In addition, the sample sizes and effect size of
each article were illustrated using funnel plot to assess pub-
lication bias (28).
RESULTS
Table 1 presents the details of the 12 studies used in the
meta-analysis. A total of 8,029 breast cancer cases were in-
cluded in the analysis. Six studies were performed in North
America, five were published each in Europe and one in Asia.
Two articles were written in the late 1980s and ten were
written after the 1990s. In one paper (23), the subjects were
women in pre-menopause. In another (29), the subjects were
in post-menopause. In the remaining studies, the analyses
of subjects were made regardless of the menopausal status.
Each study was completed at the time of death. In 4 studies
(8, 22, 34, 35), the only cause of deaths was breast cancer.
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Greenberg (1985)23 UK 582 pre >27.0 vs <20.0 1.8 (0.89-3.64)
Mohle-Boetani (1988)22 USA 838 - ≥26.2 vs ≤22.9 1.4 (1.11-1.49)
Kyogoku (1990)24 Japan 213 - ≥25 vs <20 3.89 (0.77-19.70)
Tornberg (1993)30 Sweden 1,170 - ≥28 vs ≤22 1.7 (1.2-2.3)
Eley (1994)31 USA 1,130 - 85th vs 50th % 2.5 (1.8-3.4)
Holmberg (1994)32 Norway 359 - ≥29 vs <19 5.93 (1.98-17.8)
Jain (1994)33 Canada 1,033 - >27.3 vs <22.2 0.78 (0.48-1.22)
Tonkelaar (1995)29 Netherlands 241 post ≥26 vs <26 0.95 (0.51-1.78)
Zhang (1995)34 USA 698 - >28.8 vs <24.6 1.9 (1.0-3.7)
Maehle (1996)35 Norway 1,238 - 5th vs 1st quintile 1.37 (0.99-1.90)
Galanis (1998)8 USA (Hawaii) 378 - ≥25.8 vs ≤22.6 2.2 (0.9-5.4)
Saxe (1999)36 USA 149 - >27 vs ≤27 0.74 (0.32-1.71)
Total 8,029
First author Country BMI* Cut-off No. of subjects Menopausal status Hazard ratio (death)
Table 1. Characteristics of studies for meta-analysis
*BMI: body mass index.
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Fig. 1. Effect sizes, overall effect size, and their 95% confidence
intervals for body mass index and prognosis in breast cancer by
study.
For this study, we selected death as a standard for analysis
regardless of the cause of death.
A homogeneity test was performed to check the results of
each study. The statistical Q-value was 30.88, which is larger
than the critical value of 19.67 when the degree of freedom
is 11. No homogeneity was found, and therefore, all 12 stud-
ies were heterogeneous.
Fig. 1 shows the effect sizes and 95% CI of each study, and
the overall effect size determined by meta-analysis. Three of
the twelve studies only reported that the effect size was less
than 1 and the remaining nine studies reported that the effect
size was greater than 1. However, only five studies men-
tioned the statistical significance of these results. Using the
random-effects model (27), which accounted for hetero-
geneity across the 12 studies, estimates based on an overall
effect size for BMI and prognosis in breast cancer found to
be 1.56 (95% CI, 1.22-2.00), which was statistically signif-
icant (Table 2). 
Inverse funnel plotting between sample size and the effect
sizes for each study is shown in the log scale (Fig. 2). The
scatter of points showed that the studies were concentrated
at the right lower and middle part of the triangle. There-
fore, studies with a large number of breast cancer patients
were lacking.
DISCUSSION
Studies on obesity and prognosis in breast cancer have been
undertaken since the late 1970s. In this study, a meta-anal-
ysis was performed to integrate the relationship between
BMI as an index of obesity and prognosis in breast cancer.
We observed that high BMI had a bad affect on the progno-
sis in breast cancer with a statistical significance in this
study. 
However, because the information used in this study was
based on observational studies, the confounding effect of
each of the study variables should be accounted for when
estimating the relationship between BMI and the prognosis
of a breast cancer patient. Also, because the terms of reference
of BMI used in each study were different, we were present-
ed with limitations in the terms of explaining this result.
Only the highest and lowest hazard ratio of BMI were inte-
grated, and therefore, this study does not purport the relation-
ship between BMI and prognosis in breast cancer across the
BMI range. For these reasons, we thought that the strength
of effect size did not mean the absolute value, while it did
suggest the possibility of BMI as a prognostic factor related
to the prognosis of breast cancer. 
Subjects of each study were the patients who had been list-
ed as having breast cancer in their community cancer reg-
istry, who had had a diagnosis at a defined group and were
followed up prospectively, who had had medical treatment
at specific hospitals, or who had been assigned to patient
groups in a case-control study. Different methods of subject
selection might also have influenced the results of this study.
Since six studies were published in North America, five in
Fixed effect 1.54 1.35-1.75
Random effect 1.56 1.22-2.00
Model Overall effect size 95% confidence interval
Table 2. The overall effect size and 95% confidence interval
for body mass index and prognosis in breast cancer accord-
ing to statistical model
Nu
m
be
r o
f s
ub
jec
ts
Log hazard ratio
1,400
1,200
1,000
800
600
400
200
0
-5 0.0 0.5 1.0 1.5 2.0
Fig. 2. Funnel plotting of sample size and the logarithm of the
hazard ratio of body mass index and prognosis in breast cancer
by study.
Europe, and one in Asia, it is possible that racial and envi-
ronmental factors might also have influenced the results. In
addition, an inconsistency might have existed in terms of
the definition of death and the time of the final observation.
In this study, there was a lack of clarity in terms of the recog-
nition of the termination of study, and we will emphasize
the importance of this particular aspect in further study.
We integrated the results of the studies chosen, which
were based on effect size and 95% CI for each study using
the fixed effects model and the random effects model. When
the fixed effect model is used to integrate the results of
studies, a homogeneity test is necessary (27). The hypothe-
sis that the magnitude of the effect size was homogeneous
was not accepted, and it was shown that the results of the
studies incorporated into this analysis were heterogeneous.
Because of diversity in the design and analysis of the various
studies, we assumed that the effect size being estimated
would vary among the studies. For example, due to differ-
ent study population (nations, menopausal status, etc.) and
the BMI cut-offs for the comparisons the true effects would
vary. To account for several sources of variation in this study,
DerSimonian and Laird had employed a random effects
model to take account of the variation in the true effects of
the studies being combined. Rather than rely on tests of
homogeneity to establish the validity of the analysis, we
assumed heterogeneity and employed the random effects
models (Table 2) as developed by DerSimonian and Laird
(27).
The findings of some meta-analyses have later been con-
tradicted by large randomized controlled trials (38). Such
discrepancies have brought discredit to a technique that has
been controversial since its outset. The avoidance of mis-
leading meta-analysis necessarily involves considerations of
the existence of publication bias and the many other biases
that may be introduced into the process of locating, selecting,
and combining studies (28, 39-41). Funnel plots, plots of
the trials’effect estimates against sample size, may be useful
to detect the validity of meta-analyses, including publica-
tion bias, etc. (28, 42). In this study, the possibility of pub-
lication bias was assessed using funnel plots. Funnel plot
asymmetry is shown in areas with many subjects and large
effect size (Fig. 2). We do not believe publication bias to be
the source of asymmetry in this study. Rather, we think that
the asymmetry may have been caused by the lack of the incor-
poration of larger-scale studies. As an evidence, although
studies on the relationship between obesity and the progno-
sis in breast cancer have been conducted since the late 1970s
(21), articles have only been published from 1990.
The primary targets of meta-analysis are randomized clin-
ical trials in which there is little possibility of a bias interven-
ing in the individual research project. Thus, a number of
drawbacks are indicated in the application of this method to
observational researches, and a considerable debate contin-
ues as to the merits of meta-analysis in observational studies
(43-45). Nonetheless, many researchers have emphasized
the significance of meta-analysis for contributing to knowl-
edge by studying features across studies that may account
for result variations (46-48).
It is still difficult to find a large cohort study of high qual-
ity targeted at women in this area. Therefore, what we should
emphasize is not just a simple methodological application
of meta-analysis, but the necessity to conduct high quality
cohort studies and higher quantity studies related to this
issue. Only when high quality studies are performed, will
quantitative meta-analysis contribute to the integration of
high quality results.
In conclusion, our results suggest that BMI may be a prog-
nostic indicator in breast cancer.
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